American College of Obstetricians and Gynecologists Committee Opinion: Personalized Genomic Testing for Disease Risk

ABSTRACT: Advances in genetic technologies have led to the identification of hundreds of single nucleotide polymorphisms that are associated with a variety of complex diseases, including cancer, diabetes, cardiovascular disease, and Alzheimer disease. Although personalized genomic tests that provide information regarding the risk of development of multiple diseases may be important tools in the near future, their use is not recommended outside of a clinical trial until these tests are validated as clinically useful in appropriately designed prospective studies. Testing for single-gene disorders should be approached in accordance with accepted guidelines that address the evaluation and management of these specific diseases.

Type Guideline
CME Available No
Cost Free

Genomic Competencies

Experts from the disciplines listed below have tagged this resource as fulfulling genomic competencies.


  • Genomic Testing
    • P-GT2A:   Patient Care
      • 2A1:   Discuss the indications for genomic testing - specifically the benefits, risks, and alternatives
      • 2A4:   Discuss risks of having genomic testing done: e.g., psychological implications for the individual as well as the family; the potential for discrimination; and the potential effect on insurance coverage.
      • 2A7:   Provide referral to an appropriate specialist for genomic testing of a condition outside the physician’s scope of practice
    • P-GT2D:   Interpersonal and Communication Skills
      • 2D3:   Facilitate access to resources to enhance patient learning about the results of genomic testing
    • P-GT2E:   Professionalism
      • 2E1:   Be aware of and comply with local and federal laws and regulations regarding use of genomic tests
    • P-GT2G:   Interprofessional Collaboration
      • 2G1:   Initiate responsible referrals to specialists or other health professionals
    • P-GT2H:   Personal and Professional Development
      • 2H1:   Engage in continuing education regarding advances in genomic medicine and changing indications for and interpretation of genomic testing